Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Capitalization 4.65B 6.32B P/E ratio 2024 *
101x
P/E ratio 2025 * 76.6x
Enterprise value 2.69B 3.66B EV / Sales 2024 *
10.8x
EV / Sales 2025 * 8.24x
Free-Float
96.8%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.94%
1 week-14.87%
Current month-19.27%
1 month-16.70%
3 months-6.21%
6 months+62.01%
Current year+71.90%
More quotes
1 week
133.36
Extreme 133.36
150.60
1 month
133.36
Extreme 133.36
177.37
Current year
69.43
Extreme 69.43
177.37
1 year
36.42
Extreme 36.4201
177.37
3 years
10.00
Extreme 10
177.37
5 years
10.00
Extreme 10
177.37
10 years
10.00
Extreme 10
177.37
More quotes
Director TitleAgeSince
Founder 55 98-07-31
Director of Finance/CFO 56 15-02-28
Chief Operating Officer 41 23-02-01
Manager TitleAgeSince
Founder 55 98-07-31
Chairman 79 10-12-31
Director/Board Member 76 16-01-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-2.61%-14.87%+131.65%+327.47%4.65B
+0.61%+2.93%+20.44%+9.14%237B
+0.60%+3.97%+10.61%-16.75%197B
+1.01%+0.17%+62.38%+41.94%170B
+0.50%+2.37%+54.19%+86.82%122B
-0.46%-4.24%+11.64%-12.94%61.72B
+0.20%-2.62%-7.22%-27.34%40.89B
-0.04%-0.67%+21.09%-22.12%39.68B
+2.18%-2.34%-9.36%-44.46%39.58B
+0.51%+0.88%+31.82% - 38.87B
Average +0.42%-1.45%+32.72%+37.97% 95.17B
Weighted average by Cap. +0.60%+1.33%+28.26%+14.83%
See all sector performances
2024 *2025 *
Net sales 444M 604M 579M 788M
Net income 47.32M 64.37M 63.89M 86.92M
Net Debt 143M 194M 123M 167M
More financial data * Estimated data
Logo TransMedics Group, Inc.
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Employees
584
Related indices
More about the company
Date Price Change Volume
24-09-10 135.68 $ -2.61% 689,193
24-09-09 139.31 $ -0.41% 929,993
24-09-06 139.88 $ -2.44% 1,542,732
24-09-05 143.38 $ -5.03% 1,658,717
24-09-04 150.98 $ -5.27% 1,046,732

Delayed Quote Nasdaq, September 10, 2024 at 04:00 pm

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
135.68USD
Average target price
179.44USD
Spread / Average Target
+32.26%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW